Skip to main content

Table 5 Results of this analysis

From: Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Endpoints

OR with 95% CI

P value

I2 (%)

Any AE

1.00 [0.81–1.24]

1.00

0

Headache

0.88 [0.67–1.27]

0.49

0

Nasopharyngitis/URI

0.95 [0.71–1.27]

0.75

6

Back pain

0.81 [0.49–1.33]

0.40

0

Dizziness

0.63 [0.43–0.92]

0.02

0

Diarrhea

0.83 [0.48–1.44]

0.52

0

Nausea

0.52 [0.25–1.05]

0.07

0

Weight gain

2.29 [0.51–10.34]

0.28

80

Peripheral edema

1.21 [0.56–2.62]

0.63

76

  1. Nasopharyngitis and upper respiratory tract infection were combined together during the analysis
  2. Abbreviations: URI upper respiratory infection, AE adverse events, OR odds ratio, CI confidence interval